This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain and Northern Ireland. IBRANCE® (palbociclib) Prescribing Information for Great Britain and Northern Ireland click here.  Adverse event reporting information can be found at the bottom of the page.

IBRANCE® Dispense and Delivery Service

The IBRANCE® Dispense and Delivery Service provides home delivery to registered patients:

  • Offered to all eligible new or existing stable on medicine patients considered appropriate by the HCP
  • Patients must be treated in accordance with the SmPC1
  • This service is funded by Pfizer Ltd, the manufacturer of IBRANCE® (palbociclib) and is provided by Alcura on behalf of Pfizer Ltd.

Scope

The dispense and delivery service covers:

  • Delivery to the patients home, workplace or a friend or relative
  • ​​​​​​​Telephone and email support for enrolled patients
  • Monitoring of a patient’s drug supply
  • Delivery arranged using phone or online booking
  • All available strengths/ formulations of the medicine

Delivery

Deliveries will be dispensed by the Alcura pharmacy and delivered by a dedicated national courier.

Standard delivery
Monday to Friday: 8:00 am – 6:00 pm
Saturday: 8:00 am – 12:00 pm

Extended delivery
Tuesday to Saturday: 9:00 am – 9:00 pm

Urgent deliveries
Next day when required

Same day delivery in urgent or emergency situations
Patients have access to a telephone line and email for delivery queries

Please click on the video below for an illustration of the IBRANCE® Dispense and Delivery Service.

Please contact your local Pfizer Healthcare Partnership Manager for more details


References
  1. IBRANCE® Summary of Product Characteristics for Great Britain click here. IBRANCE® Summary of Product Characteristics for Northern Ireland click here.
PP-IBR-GBR-4025. April 2022

Resources

Resources to assist you and your patients
  • Adapting Breast Cancer Care during COVID-19 Pandemic
  • NMP Service Resources
  • mBC Models of Care
    ​​​​​​​
    Materials

    Videos

Indication

  • IBRANCE® is indicated for the treatment of HR+/HER2- locally advanced or metastatic breast cancer:
       - In combination with an aromatase inhibitor; or
    ​​​​​​​   - In combination with fulvestrant in women who have received prior ET

    In pre- or perimenopausal women, the ET should be combined with a LHRH agonist

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?